Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.63 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | BCR | P11274 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722198 | 0.89 | PDPK1 (0.77) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL17704291 | 0.80 | PDPK1 (0.65) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL19219079 | 0.78 | PDPK1 (0.63) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL21791658 | 0.78 | LOXL2 (0.71) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL5147639 | 0.78 | PDPK1 (0.91) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL466426 | 0.78 | PDPK1 (0.63) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL10576999 | 0.78 | PDPK1 (0.63) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL16119908 | 0.78 | PDPK1 (0.63) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL3885226 | 0.78 | LOXL2 (0.66) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL4589649 | 0.78 | PDPK1 (0.63) | PDPK1LOXL2ADRB2CYP2A6ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364244-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY | Ashvattha Therapeutics, Inc. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230233696-A1 | TRIANTENNARY N-ACETYLGALACTOSAMINE MODIFIED HYDROXYL POLYAMIDOAMINE DENDRIMERS AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. (US) | 2023-07-27 | — | — | US | disclosed |
| CN-116249558-A | Dendrimer compositions and methods for drug delivery to injured kidneys | 阿什瓦塔治疗股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-4181913-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY | Ashvattha Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| US-11241420-B2 | Compositions and methods for prophylaxis and treatment of addictions | OMEROS CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| WO-2022016120-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY | Ashvattha Therapeutics, Inc. (US) | 2022-01-20 | — | — | WO | disclosed |
| WO-2021113657-A1 | TRIANTENNARY N-ACETYLGALACTOSAMINE MODIFIED HYDROXYL POLYAMIDOAMINE DENDRIMERS AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20190022077-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OMEROS CORPORATION | 2019-01-24 | — | — | US | disclosed |
| EP-3398599-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | Omeros Corporation (US) | 2018-11-07 | — | — | EP | disclosed |
| US-10064850-B2 | Compositions and methods for prophylaxis and treatment of addictions | OMEROS CORPORATION (US) | 2018-09-04 | — | — | US | disclosed |
| US-20170027920-A1 | Compositions and Methods for Prophylaxis and Treatment of Addictions | OMEROS CORPORATION | 2017-02-02 | — | — | US | disclosed |
| US-20160331729-A9 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OMEROS CORPORATION (US) | 2016-11-17 | — | — | US | disclosed |
| US-20130296347-A1 | Compositions and Methods for Prophylaxis and Treatment of Addictions | OMEROS CORPORATION | 2013-11-07 | — | — | US | disclosed |
| CN-102348457-A | Compositions and methods for preventing and treating addiction | OMEROS CORP | 2012-02-08 | — | — | CN | disclosed |
| EP-2405914-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | Omeros Corporation (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010105103-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OMEROS CORPORATION (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234413-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OMEROS CORPORATION (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234413-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OPRK1, OPRL1, PPARA | PDPK1 629/4885LOXL2 2644/4885ADRB2 128/4885 |
| US-20160331729-A9 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OPRK1, OPRL1, PPARA | PDPK1 629/4885LOXL2 2644/4885ADRB2 128/4885 |
| US-20230233696-A1 | TRIANTENNARY N-ACETYLGALACTOSAMINE MODIFIED HYDROXYL POLYAMIDOAMINE DENDRIMERS AND METHODS OF USE THEREOF | FUT6, FUT5, OGT | PDPK1 3471/4885LOXL2 1231/4885ADRB2 3155/4885 |
| US-10064850-B2 | Compositions and methods for prophylaxis and treatment of addictions | OPRK1, OPRL1, OPRD1 | PDPK1 643/4885LOXL2 2565/4885ADRB2 126/4885 |
| US-20170027920-A1 | Compositions and Methods for Prophylaxis and Treatment of Addictions | OPRK1, OPRL1, PPARA | PDPK1 629/4885LOXL2 2644/4885ADRB2 128/4885 |
| US-20190022077-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OPRK1, OPRL1, PPARA | PDPK1 629/4885LOXL2 2644/4885ADRB2 128/4885 |
| US-20130296347-A1 | Compositions and Methods for Prophylaxis and Treatment of Addictions | OPRK1, OPRL1, PPARA | PDPK1 629/4885LOXL2 2644/4885ADRB2 128/4885 |
| US-20230364244-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY | PPARA, PPARD, PPARG | PDPK1 519/4885LOXL2 3254/4885ADRB2 49/4885 |
| US-11241420-B2 | Compositions and methods for prophylaxis and treatment of addictions | OPRK1, OPRL1, PPARA | PDPK1 629/4885LOXL2 2644/4885ADRB2 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.